The DOI matches its Crossref record.
Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis
Open accessAbstract
Objective: In rheumatoid arthritis (RA), B cell depletion occurs in all patients treated with rituximab, but the clinical responses to rituximab are variable. A highly sensitive assay was used to test the hypothesis that B cell depletion is variable, and that incomplete depletion leads to a poorer outcome. Methods: Sixty patients with active RA unresponsive to anti–tumor necrosis factor agents received two 1‐gram infusions of rituximab. B cell numbers were measured by highly sensitive flow cytometry before and after each infusion and at 3‐month intervals thereafter. A reduction in B cell levels below 0.0001 × 10 9/liter was defined as complete depletion (compared with 0.05 × 10 9/liter by conventional cytometry). Clinical responses were measured using the European League Against Rheumatism (EULAR) criteria. Results: At 6 months, 92% of patients had a moderate‐to‐good clinical response according to the EULAR criteria. B cells were detected in 63% of patients after the first infusion of rituximab (median level 0.0009 × 10 9/liter [range <0.0001–0.0015 × 10 9/liter), and these patients had poorer clinical outcomes than patients with complete depletion. At 9 months, 82% of patients with complete depletion had a moderate‐to‐ good EULAR response, compared with 43% of those with partial depletion (P = 0.01). At 12 months, 59% of complete responders had a moderate‐to‐good EULAR response, compared with 21% of those with partial depletion (P = 0.01). Patients in whom B cells were depleted only after the second infusion did no better than those in whom depletion was never complete and had poorer clinical outcomes than those in whom depletion was initially complete. Conclusion: This study is the first to show, using a highly sensitive analysis, that rituximab therapy is associated with variable diminution in B cell numbers. A lack of complete depletion of B cells after 1 infusion was associated with a poorer outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G., Dörner, T., Ferraccioli, G., Gottenberg, J.-E., Isaacs, J., Kvien, T. K., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144998 · Cited by 453
Self-citationvan Assen, S., Holvast, A., Benne, C. A., Posthumus, M. D., van Leeuwen, M. A., Voskuyl, A. E., Blom, M., Risselada, A. P., de Haan, A., Westra, J., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25033 · Cited by 371
Humby, F., Durez, P., Buch, M. H., Lewis, M. J., Rizvi, H., Rivellese, F., Nerviani, A., Giorli, G., Mahto, A., Montecucco, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32341-2 · Cited by 329
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
Pellkofer, H. L., Krumbholz, M., Berthele, A., Hemmer, B., Gerdes, L. A., Havla, J., Bittner, R., Canis, M., Meinl, E., Hohlfeld, R., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182152881 · Cited by 296
B cells as therapeutic targets in SLE
Sanz, I., & Lee, F. E.-H. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.68 · Cited by 261
Metadata
- Authors
- Dass, S., Rawstron, A. C., Vital, E. M., Henshaw, K., McGonagle, D., & Emery, P.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2008-09-29
- Volume
- 58
- Issue
- 10
- Pages
- 2993-2999
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2004348520
- Cited by
- 210
- References
- 0
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.